-
公开(公告)号：US11419821B2
公开(公告)日：2022-08-23
申请号：US16103192
申请日：2018-08-14
Applicant: Curemark, LLC
Inventor： Joan M. Fallon , Matthew Heil
IPC: A61K38/54 , A61K38/48 , A61K9/16 , A61K9/50 , A23L33/17 , A61K38/46 , A61K38/47 , A61J15/00 , A61K9/00 , A61K9/107
Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
-
公开(公告)号：US20190275066A1
公开(公告)日：2019-09-12
申请号：US16422079
申请日：2019-05-24
Applicant: Curemark, LLC
Inventor： Joan M. Fallon , Richard Feltenstein
IPC: A61K31/7016 , A61K31/047 , A61K31/045 , A61K31/7012
Abstract: A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.
-
公开(公告)号：US09345721B2
公开(公告)日：2016-05-24
申请号：US14087930
申请日：2013-11-22
Applicant: Curemark LLC
Inventor： Joan M. Fallon , Richard Feltenstein
IPC: A61K31/7016 , A61K35/37 , A61K31/045 , A61K31/7012
CPC classification number: A61K31/7016 , A61K31/045 , A61K31/047 , A61K31/7012
Abstract: A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.
Abstract translation: 一种治疗自闭症，其中施用有效量的乳果糖以便结合胃肠道，血液和神经系统中的过量氨，以防止或逆转由施用某些抗生素引起的氨中毒。 结肠中的乳果糖分子被某些细菌发酵。 发酵过程降低了结肠pH，细菌形成氨离子的氨被氨基酸和蛋白质合成使用。 这降低了血清氨水平，降低了神经毒性。
-
公开(公告)号：US20150273030A1
公开(公告)日：2015-10-01
申请号：US14713178
申请日：2015-05-15
Applicant: Curemark, LLC
Inventor： Joan M. Fallon
CPC classification number: A61K38/54 , A61K36/185 , A61K38/465 , A61K38/47 , A61K38/4826 , A61K38/4873 , C12Q1/37 , C12Y301/01 , C12Y302/01 , C12Y304/00 , C12Y304/21001 , C12Y304/21004 , C12Y304/22002 , G01N33/6896 , G01N2333/976 , G01N2800/2828 , G01N2800/52 , A61K2300/00
Abstract: A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed.
Abstract translation: 公开了治疗朊病毒疾病症状的治疗组合物和治疗剂的制备方法。 治疗组合物是包含一种或多种消化和/或胰酶的稳定的药物组合物。 治疗组合物可以通过各种封装技术制造。 治疗组合物的递送可以通过注射，通过粘附药物贴剂或其它方法口服制备。 此外，公开了使用粪便胰凝乳蛋白酶水平作为朊病毒疾病存在的生物标志物的方法或个体发展朊病毒病的可能性。
-
公开(公告)号：US20150150955A1
公开(公告)日：2015-06-04
申请号：US14612580
申请日：2015-02-03
Applicant: Curemark LLC
Inventor： Joan M. Fallon , Matthew Heil
CPC classification number: A61K9/1682 , A23L33/17 , A23V2002/00 , A61J15/00 , A61K9/0053 , A61K9/009 , A61K9/1075 , A61K9/16 , A61K9/1617 , A61K9/167 , A61K9/5015 , A61K9/5063 , A61K38/465 , A61K38/47 , A61K38/48 , A61K38/4826 , A61K38/54 , C12Y301/01003 , C12Y302/01 , C12Y304/21001 , Y02A50/473 , Y02A50/481 , A61K2300/00
Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
Abstract translation: 本发明涉及包衣消化酶制剂和酶递送系统以及包含该制剂的药物组合物。 本发明还涉及用于治疗ADD，ADHD，自闭症，囊性纤维化和其他行为和神经障碍的人的系统，药物组合物和制剂的制备和使用方法。
-
Patent Agency Ranking
公开(公告)号：US20240156924A1
公开(公告)日：2024-05-16
申请号：US18327740
申请日：2023-06-01
Applicant: Curemark, LLC
Inventor： Joan M. Fallon , Matthew Heil , James Szigethy , James Fallon
CPC classification number: A61K38/54 , A61K9/0053 , A61K38/465 , A61K38/47 , A61K38/48 , A61K45/06 , A61P25/00 , C12Y301/01 , C12Y302/01 , C12Y304/00
Abstract: Described herein are compositions which include digestive enzymes which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally- or recombinantly-derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
-
公开(公告)号：US11364287B2
公开(公告)日：2022-06-21
申请号：US16422462
申请日：2019-05-24
Applicant: Curemark, LLC
Inventor： Joan M. Fallon , Matthew F. Heil , James Szigethy , James J. Fallon
Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of Celiac Disease. Also described herein is a method for treating a subject with Celiac Disease using digestive enzymes and their derivatives to alleviate the symptoms of Celiac Disease. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of Celiac Disease.
-
公开(公告)号：US20210252031A1
公开(公告)日：2021-08-19
申请号：US17306614
申请日：2021-05-03
Applicant: Curemark, LLC
Inventor： Joan M. Fallon , Richard Feltenstein
IPC: A61K31/7016 , A61K31/045 , A61K31/7012 , A61K31/047
Abstract: A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.
-
公开(公告)号：US20210145947A1
公开(公告)日：2021-05-20
申请号：US17159846
申请日：2021-01-27
Applicant: Curemark, LLC
Inventor： Joan M. Fallon , Matthew Heil , James Szigethy , James Fallon
Abstract: Described herein are compositions which include digestive enzymes which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally- or recombinantly-derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
-
公开(公告)号：US10588948B2
公开(公告)日：2020-03-17
申请号：US15074115
申请日：2016-03-18
Applicant: Curemark, LLC
Inventor： Joan M. Fallon
Abstract: A therapeutic composition for the treatment of the symptoms of Williams Syndrome and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of Williams Syndrome, or the likelihood of an individual to develop Williams Syndrome is disclosed.
-
-
-
-
-
-
-
-
-
Search Results
70
records
(took 0.045 seconds)
